Fig. 6.

Regional difference in ACM from BDNF-treated astrocytes effect on neuron viability. a Time schedule of ACM collection and treatment. ACM was prepared from astrocytes treated for 24 h with BDNF 50 ng/ml (ACM-BDNF) or without (ACM-CTRL). Q15 and Q120 cells were treated for 24 h with 3NP (10 mM) added to each ACM. Effects of ACM on viability of Q15 (b) or Q120 (c) cells were evaluated by Trypan blue exclusion assay. Data represent the mean number of viable cells/ml ± SEM of n = 4 experiments. Differences between all groups were analyzed by One-way ANOVA followed by Bonferroni’s multiple comparison post-test. ***p < 0.001 vs. DMEM and ^^p < 0.01 vs. ACM-CTRL + 3NP. d Time schedule of ACM collection and treatment. ACM was prepared from astrocytes treated for 24 h with BDNF 50 ng/ml (ACM-BDNF) or without (ACM-CTRL). Q15 and Q120 cells were treated for 24 h with 3NP (10 mM) and if necessary, ANA-12 (1 μM) was added to ACM. Q120 cells were treated with ACM from cortical (e) or striatal (f) astrocytes. Values represent the mean number of viable cells ml ± SEM of n = 4 experiments. Differences between all groups were analyzed by one-way ANOVA followed by Bonferroni’s multiple comparison post-test. **p < 0.01, ***p < 0.001 vs. control and ^^p < 0.01 vs. ACM-CTRL + 3NP